Abivax S.A.

The stock remains in a powerful multi-month uptrend and sits well above its 200-day average, with the 50-day also above the 200-day. It is trading near the upper end of its 52-week range, which keeps the regime constructive but leaves less room for error after a sharp run.

Street sentiment is firmly positive: the consensus is Buy, with 12 Buy ratings, 1 Hold, and no Sells. The average target is 145.86, and recent action has leaned higher, including Jefferies moving to Buy and Piper Sandler, Truist, and BTIG lifting targets to 175, 155, and 175.

The earnings profile is volatile but improving on select quarters, with a 4-for-7 beat rate and a recent 12.3% EPS beat in May. Next-year EPS estimates still point to a loss at -3.264, so shareholders should watch whether revenue growth and loss narrowing continue to outpace expectations.

No notable insider buying or selling in recent quarters. With no reported transactions, there is no insider signal to read into, and the stock’s setup is being driven by clinical progress and analyst sentiment rather than management trading.

The business is still loss-making, with operating margin at -41.8% and TTM EPS at -5.22, but revenue is growing 35.2% year over year. The balance sheet is a strength, with $530.2 million in cash and equivalents versus $45.9 million in debt, leaving a large net cash cushion.

As a clinical-stage biotech, ABVX screens more like a catalyst-driven platform than a mature peer on earnings power. Gross margin is 100.0%, but valuation remains rich versus the sector because the story is still centered on pipeline execution and future commercialization.